Belgian Biotech’s Leukemia CAR-T Treatment Leaves Patient Cancer-Free

Celyad has announced early results from a clinical trial, where a patient has been cleared of cancer after treatment with its alternative CAR-T cell therapy.

Celyad has pioneered a unique Natural Killer Receptor (NKR) T cell platform for the treatment of cancer, a potential €100B market. Early results from its Phase I study assessing the company’s candidate, CYAD-01, saw a patient with relapsed acute myeloid leukemia (AML) achieve Morphological Leukemia-Free Status (MLFS). The next challenge is to back this up in as many clinical settings as possible.

Celyad’s technology overcomes limitations of CAR-T by stimulating natural killer (NK) cells, white blood cells that form the first line of immune defence. CYAD-01 T cells are modified with a sequence that encodes NK2GD, a receptor that activates NK cells upon interaction with its ligand. To improve the potency of the cell, co-stimulation is used. Luckily, regular T cells naturally express one of the molecules required for co-stimulation, so the construction of NKR-T cells is relatively simple.

Celyad has joined the CAR-T party, which is currently led by Novartis, with Kite Pharma not far behind. Although a patient being left cancer-free is great, we must not get carried away until we have seen it replicated in more patients.


Image – Kateryna Kon / shutterstock.com

Let's Continue The Conversation

Feel free to send us comments about this article to [email protected] and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.